Shanghai Hile Bio-Technology Co., Ltd.

Shanghai Stock Exchange 603718.SS

Shanghai Hile Bio-Technology Co., Ltd. Free Cash Flow Yield on January 27, 2025: -0.35%

Shanghai Hile Bio-Technology Co., Ltd. Free Cash Flow Yield is -0.35% on January 27, 2025, a -24.64% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Shanghai Hile Bio-Technology Co., Ltd. 52-week high Free Cash Flow Yield is -0.26% on March 22, 2024, which is 25.50% above the current Free Cash Flow Yield.
Shanghai Hile Bio-Technology Co., Ltd. 52-week low Free Cash Flow Yield is -0.43% on July 24, 2024, which is -23.50% below the current Free Cash Flow Yield.
Shanghai Hile Bio-Technology Co., Ltd. average Free Cash Flow Yield for the last 52 weeks is -0.35%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 603718.SS

Shanghai Hile Bio-Technology Co., Ltd.

CEO	Ms. Qun Lin
IPO Date	May 15, 2015
Location	China
Headquarters	Economic Development Zone
Employees	295
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers swine fever live vaccines; trivalent inactivated vaccines for piglets; inactivated vaccine for streptococcus suis; pseudorabies live vaccines; inactivated oil emulsion vaccine of porcine parvovirus disease; pathogenic porcine reproductive and respiratory syndrome live vaccines; transmissible gastroenteritis, porcine epidemic diarrhea, and porcine rotavirus triple live vaccines; porcine reproductive and respiratory syndrome live vaccines; swine transmissible gastroenteritis and swine epidemic diarrhea combined inactivated vaccines; porcine circovirus type 2 inactivated vaccines; and swine Japanese encephalitis live vaccines. It also provides chicken infectious bursal disease live vaccines; inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis, and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; avian newcastle disease and avian infectious bronchitis combined live vaccines; newcastle disease low virulent live vaccines; Marek's disease turkey herpes virus live vaccines; and fowlpox live vaccines. The company was founded in 1981 and is based in Shanghai, China.

Key trends

Past 5 years